• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

ROYALTY PHARMA PLC

Notes

No. Proposition For Against Abstain
1

Election of Director: Pablo Legorreta

2

Election of Director: Ted Love, M.D.

3

Election of Director: Bonnie Bassler, Ph.D.

4

Election of Director: Vlad Coric, M.D.

5

Election of Director: Catherine Engelbert

6

Election of Director: Carole Ho, M.D.

7

Election of Director: David Hodgson

8

Election of Director: Gregory Norden

9

Election of Director: Elizabeth Weatherman

10

A non-binding advisory vote to approve executive compensation.

11

Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.

12

Approve receipt of our U.K. audited annual report and accounts and related directors and auditors reports for the fiscal year ended December 31, 2025.

13

Approve on a non-binding advisory basis our U.K. directors remuneration report for the fiscal year ended December 31, 2025.

14

Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.

15

Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory auditor.

16

Approve the terms of the agreements and counterparties pursuant to which we may purchase our Class A ordinary shares.

17

Authorize the Board to allot shares.

18

Authorize the Board to allot shares without rights of pre-emption (special resolution).